MAP3K1 and psoriasis vulgaris: On the other hand, a recent study analyzed 124 polymorphisms of a number of candidate genes associated with response to ETN (PASI 75 at 3 and 6 months) in 78 Spanish patients diagnosed with moderate-to-severe plaque psoriasis; it found that the PTTG1 rs2431697 (T > C), MAP3K1 rs96844 (G > A) and ZNF816A rs9304742 (T > C) polymorphisms were associated with good response to ETN at 3 months of treatment (PTTG1 rs2431697-T: p = 0.04; MAP3K1 rs96844-C: p = 0.009; ZNF816A rs9304742-T: p = 0.006).